In patients with severe hepatic disease (e.g., Child-Pugh class C), can rocuronium be used and safely reversed with sugammadex?

Rocuronium with Sugammadex in Severe Hepatic Disease

Yes, rocuronium can be used in severe hepatic disease and safely reversed with sugammadex, though benzylisoquinoline muscle relaxants (atracurium/cisatracurium) are preferred as first-line agents.

Preferred Approach: Benzylisoquinoline Muscle Relaxants

The 2020 Anaesthesia guidelines explicitly recommend atracurium or cisatracurium as the preferred muscle relaxants in hepatic failure 1. These agents undergo organ-independent elimination (Hofmann degradation and ester hydrolysis), making their pharmacokinetics and pharmacodynamics similar in patients with and without liver failure 1. This eliminates the unpredictability seen with hepatically-cleared agents.

If Rocuronium is Used

Dosing Considerations

• Initial dose should NOT be modified - administer the usual intubation dose 1
• In cirrhotic patients, increased distribution volume reduces drug concentration, but this effect is clinically insignificant at intubation doses (0.6-1.2 mg/kg) 1
• Expect prolonged duration of action with repeated doses or infusions due to reduced biliary and renal clearance 1
• Wide interindividual variability exists in cirrhotic patients 1

Sugammadex Reversal

Sugammadex effectively reverses rocuronium-induced neuromuscular blockade in hepatic disease:

• Use standard sugammadex dosing based on depth of blockade 1:

  • TOF count 2-4: 2 mg/kg
  • Post-tetanic count 1-2: 4 mg/kg
  • Immediate reversal: 8 mg/kg

• Recovery times are comparable to patients with normal liver function 2, 3

• In Child-Pugh class A cirrhosis, sugammadex (2 mg/kg) achieved TOF ratio ≥0.9 in 3.1 minutes versus 14.5 minutes with neostigmine 3

• No evidence of recurarization when appropriate doses used 2

Critical Monitoring Requirements

Quantitative neuromuscular monitoring is mandatory 1:

• Monitor throughout the case to guide redosing
• Continue monitoring after sugammadex administration to detect potential recurarization 1
• Adjust maintenance doses based on TOF response given unpredictable duration in cirrhosis

Special Considerations for Severe Hepatic Disease

The 2025 EASL guidelines for cirrhotic patients undergoing surgery recommend:

• Atracurium and cisatracurium are suitable as they don't rely on hepatic excretion 4
• Sugammadex rapidly antagonizes moderate residual rocuronium-induced neuromuscular block in Child-Pugh class A patients undergoing hepatic resection 4
• Neuromuscular block monitoring is recommended 4

Important Caveats

1. Avoid repeated rocuronium dosing or continuous infusion - duration becomes highly unpredictable in cirrhosis 1

2. Sugammadex is renally eliminated - while effective in hepatic disease, be aware that coexisting renal dysfunction (common in advanced cirrhosis) prolongs sugammadex elimination 5

3. Not recommended for rapid sequence intubation in severe cirrhosis - the FDA label notes rocuronium should be used with caution in significant hepatic impairment, and higher doses may be needed in patients with ascites (though duration will be prolonged) 6

4. Child-Pugh class B/C patients - limited data exists for severe cirrhosis beyond class A. The research evidence primarily involves Child-Pugh A patients 3, 7

Practical Algorithm

For elective surgery in severe hepatic disease:

1. First choice: Atracurium or cisatracurium (predictable pharmacokinetics)
2. If rocuronium used: Standard intubation dose, avoid maintenance dosing if possible
3. Reversal: Sugammadex at standard doses based on TOF monitoring
4. Essential: Continuous quantitative neuromuscular monitoring

For emergency/rapid sequence intubation:

• Consider succinylcholine if no contraindications
• If rocuronium necessary, may need higher initial dose in ascites but expect prolonged duration 6

The combination is usable and effective, but the unpredictable prolongation of rocuronium in cirrhosis makes benzylisoquinoline agents the safer, more predictable choice.